Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer

The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor-positive (ER+), HER2- breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women. Tumor samples from 385...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2022-10, Vol.28 (20), p.4435-4443
Hauptverfasser:	Constantinidou, Anastasia, Marcou, Yiola, Toss, Michael S, Simmons, Timothy, Bernhisel, Ryan, Hughes, Elisha, Probst, Braden, Meek, Stephanie, Kakouri, Eleni, Georgiou, Georgios, Zouvani, Ioanna, Savvidou, Gabriella, Kuhl, Vanessa, Doedt, Jennifer, Wagner, Susanne, Gutin, Alexander, Slavin, Thomas P, Lanchbury, Jerry S, Kronenwett, Ralf, Ellis, Ian O, Rakha, Emad A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - genetics Chemotherapy, Adjuvant Female Humans Menopause Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Precision Medicine and Imaging Prognosis Receptor, ErbB-2 - genetics Receptor, ErbB-2 - therapeutic use Receptors, Estrogen - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!